-
Temtokibart Shows Benefit, Effect on Biomarkers in Phase 2b Atopic Dermatitis Trial
18 Sep 2025 12:49 GMT
… moderate-to-severe atopic dermatitis.
Presented as late-breaking … used to treat atopic dermatitis” said Stephan Weidinger, MD … moderate-to-severe atopic dermatitis. The primary endpoint is … moderate-to-severe atopic dermatitis still face numerous unmet …
-
Experts Urge Curbing Systemic Steroids in Atopic Dermatitis
18 Sep 2025 10:31 GMT
… corticosteroid (SCS) use in atopic dermatitis (AD), the practice remains widespread …
-
Bridging Healing Paths: Understanding Irritant Contact Dermatitis in Allopathic and Homoeopathic Paradigms
18 Sep 2025 01:30 GMT
… strategy for managing contact dermatitis and improving patient outcomes.
… Keywords:- Contact Dermatitis, Allopathy, Homoeopathy, Comparative Study, … Perspective :- Irritant contact dermatitis develops primarily due to disruption …
-
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight
17 Sep 2025 22:54 GMT
… especially moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis … inflammatory pathways in atopic dermatitis and other dermatoses.
Interleukin … overlapping inflammatory pathways in atopic dermatitis and other dermatologic conditions. …
-
<![CDATA[Real-World Data Shed Light on Abrocitinib Use for Atopic Dermatitis, With Raj Chovatiya, MD, PhD]]>
17 Sep 2025 19:24 GMT
… ) in patients with atopic dermatitis.
“One of the things … moderate-to-severe atopic dermatitis who received abrocitinib between … rhinitis (38.7%), contact dermatitis (37.8%), and depression … Moderate-to-Severe Atopic Dermatitis Observed in Electronic Health …
-
Canine Atopic Dermatitis Market to Reach US$ 431.0 Mn by 2035, Growing at 5.8% CAGR | TMR
17 Sep 2025 17:15 GMT
… leading the global canine atopic dermatitis market, ranging from pharmaceutical companies … a groundbreaking treatment for atopic dermatitis in dogs.
Recent Developments
1 …
Market Segmentation
The canine atopic dermatitis market can be segmented as …
-
#EADV25: Leo Pharma details mid-stage win for IL-22 targeting antibody in atopic dermatitis
17 Sep 2025 14:19 GMT
-
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
17 Sep 2025 11:00 GMT
… a preclinical model of atopic dermatitis (AD). “As a potent, orally … barrier function in a mouse dermatitis model.
Gilead exercised its option … multiple inflammatory diseases, including atopic dermatitis; the therapeutic potential of IRAK4 …
-
No camouflaging success of Apollo Therapeutics' atopic dermatitis CHAMELEON trial
17 Sep 2025 01:49 GMT
… moderate to severe atopic dermatitis (AD). The trial … for patients with atopic dermatitis. We also believe camoteskimab … initial focus on atopic dermatitis. There are multiple additional … different dosing frequencies.
Atopic dermatitis is the most common …
-
<![CDATA[Camoteskimab Meets Primary Endpoint in Phase 2a Clinical Trial in Atopic Dermatitis]]>
16 Sep 2025 19:51 GMT
… use of camoteskimab in atopic dermatitis (NCT06436183).
“This data confirms that … for inflammatory conditions, with atopic dermatitis as its lead indication.
There … al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and …
About
© 1995-2025